Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | Exciting advances in the field of CLL

Christine Ryan • 10 Jun 2022
EHA 2022
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Obinutuzumab

Christine Ryan, MD, Dana-Farber Cancer Institute, Boston, MA, shares her excitement for advances in targeted therapies for chronic lymphocytic leukemia (CLL), including next-generation BTK inhibitors. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Christine Ryan

The management of elderly patients with CLL 0:33
The management of elderly patients with CLL
Christine Ryan • 10 Jun 2022
Results of a Phase Ib study of ibrutinib + obinutuzumab in R/R CLL 2:58
Results of a Phase Ib study of ibrutinib + obinutuzumab in R/R CLL
Christine Ryan • 10 Jun 2022

Related Videos

Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia 1:48
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia
Michael Savona • 6 Dec 2025
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML 1:31
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Wei-Ying Jen • 6 Dec 2025
The development and international validation of an unsupervised classification model in AML 1:28
The development and international validation of an unsupervised classification model in AML
Amin Turki • 7 Dec 2025
The potential association of plasma venetoclax level with treatment efficacy in first-line AML 2:08
The potential association of plasma venetoclax level with treatment efficacy in first-line AML
Thomas Cluzeau • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals